Our findings demonstrate that RBM47- and PTBP1-mediated alternative splicing of KRAS contributes to enhanced tumor progression, highlighting KRAS alternative splicing as a promising therapeutic target for cancer treatment. Here, RBM47 is linked to neoplasm.